

How the analysts reacted to the first Solvency II disclosures

Fulin Liang & Nick Ford Chair: John Lim

Fulin Liang +44 2076771464 Fulin.Liang@Morganstanley.com Equity Analyst Morgan Stanley & Co. International plc

This article is not an offer to buy or sell any security/instruments or to participate in a trading strategy. For important current disclosures that pertain to Morgan Stanley, please refer to the disclosures regarding the issuer(s) that are the subject of this article on Morgan Stanley's disclosure website. <u>https://www.morganstanley.com/researchdisclosures</u>. Morgan Stanley slides are clearly delineated.

23 November 2017

What happened during the first 18 months

Analyst view

Positives of Solvency II

- -Greater consistency than pre-SII
- -Increased transparency on local EEA entities
- -More non-life disclosures


However...

- -No more PRA return means less disclosures
- -Reduced/Removed embedded value disclosure, especially the movement analysis

-Unfair to UK names...



SFCR publication was less eventful than expected





SFCR publication was less eventful than expected





SFCR publication was less eventful than expected





Solvency II cover ratios and target ranges

Solvency II cover ratios (Own funds over SCR) ranked by HY 17 decreasing order and target ranges.



Note: ND = not disclosed

(a) Please note that the information presented here was disclosed in EUR and converted to GBP at the exchange rate as at 30 June 2017.

(b) The ratio disclosed for these companies includes a TMTP recalculation for HY 2017.

(c) The results are stated as being estimated. In reality, it is likely that all results are estimated but other companied did not explicitly disclose this.

(d) Results for Prudential presented on a 'shareholder view' basis which excludes the contribution from the with-profits funds (WPF) and staff pension schemes.

(e) Results for Phoenix represent a pro forma position which includes the impacts of the US\$500 million Tier 2 bond issued in July 2017.



Solvency II capital generation – HY17

£bn or %	Opening	Operating return	Market movements	Dividends / debt payments	Management actions	Regulatory / model changes	Other	Closing
Aegon	157%	+3%	+3%	n/d	+7%	+15%	-	185%
Aviva	11.3	0.9	(0.2)	(1.0)	0.4	-	-	11.4
AXA	197%	+9%	+1%	-5%	n/d	n/d	-2%	201%
L&G	5.7	0.9	0.1	(0.6)	0.6	-	-	6.7
Old Mutual	122%	n/d	n/d	n/d	11%	-	-3%	130%
Phoenix	1.1	0.2	(0.1)	(0.2)	0.2	-	0.5	1.7
Prudential	12.5	1.7	-	(0.8)	-	-	(0.5)	12.9

Source: Analysis using public market disclosures


Inconsistency examples

•Operating return includes capital actions and amortisation of TMTP for some companies but not others – some gave very little insight behind the operating return. Classification of debt and corporate centre costs was also inconsistent.

•Some included notional dividend payments for the first half of 2017



Solvency II capital generation – analyst view




Prudential plc.

Analysis of movement in Group shareholder Solvency II surplus²⁰

	2016 £bn	2015 £bn
Estimated Solvency II surplus at 1 January/economic capital surplus at 1 January	9.7	9.7
Operating experience	2.7	2.4
Non-operating experience (including market movements)	(1.1)	(0.6)
Other capital movements		
Subordinated debt issuance	1.2	0.6
Foreign currency translation impacts	1.6	0.2
Dividends paid	(1.3)	(1.0)
Methodology and calibration changes	(0.3)	(1.6)
Estimated Solvency II surplus at 31 December	12.5	9.7


Aviva





Institute and Faculty of Actuaries

Wish list - movement analysis





Recalculation of TMTP – disclosure at HY17

HY17	Aviva	L&G	Prudential	Phoenix	Standard Life	Royal London	PIC	Just Group
Allow for HY17 recalc for market changes	\checkmark	~	\checkmark	~	×	×	×	×
Allow amortisation of half year	\checkmark	✓	\checkmark	×	×	×	n/d	✓
Included disclosure of run off of TMTP	×	×	×	×	×	×	×	×
Stated size of TMTP	×	×	✓ (£2.1bn)	×	×	√ (9%)	×	×
Stated impact of HY17 recalc	✓ (£0.5bn)	✓ (£0.2bn)	✓ (£0.7bn)	×	×	×	✓ (marginal)	√ (£63m or 5%)


YE16	Aviva	L&G	Prudential	Phoenix	Standard Life	Royal London	PIC	Just Group
Allow for YE16 recalc for market changes	✓	✓	~	~	✓	×	×	×
Allow amortisation of one year	✓	✓	✓	✓	\checkmark	n/d	n/d	✓
Included disclosure of run off of TMTP	×	×	~	~	√	×	×	×
Stated size of TMTP	×	×	√ (£2.5bn)	√ (£1.9bn)	✓ (£1.5bn)	✓ (10%)	×	×
Stated impact of YE16 recalc	✓ (£0.4bn)	×	√ (£0.4bn)	√ (£0.3bn)	×	×	×	✓ (2-3%)



Institute and Faculty of Actuaries

Selected TMTP, MA and VA impacts – from SFCRs

Impact on coverage ratio of removing TMTP and MA



Solvency II coverage ratio

Solvency II coverage ratio without TMTP

Solvency II coverage ratio without MA

Solvency II coverage ratio without TMTP and MA

Source: Analysis based on S.22.01 QRT from SFCRs



Solvency II cover ratios (different views)

Solvency II shareholder/investor view vs regulatory view

	Shareholder/In	nvestor view	Regulatory view		
	HY17	YE16	HY17	YE16	
Standard Life	220%	214%	182%	177%	
Royal London	203%	232%	149%	155%	
Prudential	202%	201%	ND	ND	
Aviva	193%	189%	170%	167%	
L&G	186%	171%	180%	165%	
Phoenix	166%	139%	137%	123%	
LBG	152%	147%	147%	143%	

Solvency II Pillar 2 ratios


Generali, L&G and Just Group continue to present a Pillar 2 view as well.

Additional information

- Restrictions removed include:
 - With profits funds
 - Pension Schemes
 - Other unrecognised capital (e.g. fungibility / transferability restrictions)
- Some companies allow for other 'proforma' adjustments that they cannot allow for in the regulatory view e.g. internal model change that hadn't been approved at valuation date
- Most companies provide the restrictions in £ amounts as well
- The regulatory view presented in this table is from the market disclosure, not from the SFCR. There are some differences between these likely due to an estimate being used in the market disclosure.



SCR by risk type and diversification benefit – YE16



Pre / Post - Diversified capital YE16 rank by % size of Div. Benefit

Source: Analysis using public market disclosures

(b) Based on their shareholder SII view.




Institute and Faculty of Actuaries

Interest rates sensitivity


Interest rate +50bps

Interest rate -50bps





Credit Corporate sensitivity



A spread narrowing was also disclosed by: RSA Delta Lloyd Standard Life Aviva

Based on SII shareholder surplus Notes:

Based on SII regulatory ratio

Based on SII Shareholder ratio

Based on SII Internal view ratio


- (a) Stresses have been 'normalised' by linear interpolation for comparison purposes.
- (b) Delta Lloyd Included movement in VA. For all credit spreads (excl. mortgages).
 - (c) L&G assumed a level addition to all ratings.
 - (d) Munich Re widen both government and corporate bonds
- (e) Old Mutual assumes a 100bps increase in credit spreads is generally assumed to be a one notch downgrade from BBB to BB- rating and a two notch downgrade on lower graded investments.
- (f) BUPA assumed no credit transaction.
- (g) RSA used a parallel shift.



Equity risk sensitivity

Aegon (a) -1% Old Mutual 1% Aviva (a) 5% Allianz (a) 5% AXA 6% L&G (a) 6% Generali (a) 9% Munich Re (a) 13% Delta Lloyd (a) 13% Standard Life(a) 16% relative -5% 0% 5% 10% 15% 20%

Equity Risk +25%



Equity Risk -25%

Based on SII shareholder surplus Based on SII regulatory ratio Based on SII Shareholder ratio Based on SII Internal view ratio


Notes: (a)

Stresses have been 'normalised' by linear interpolation for comparison purposes.



Risk Margin metrics









Source: Analysis from QRTs within SFCRs

Loss absorbing capacity




LACDT / SCR pre LACDT





Source: Analysis from S.25 QRTs from SFCRs

Quality of capital



Quality of capital by Solvency II Tier as at YE16

Note: n/d = Not disclosed (a) Shareholder view Source: Analysis using public market disclosures



Embedded value & new business

- EV disclosures continue to decrease particular in UK
- Various different definitions of EV used, including some based from SII as a starting point
- Similarly, various different measures for new business

	EV	VNB
Aegon	n/a	MCVNB
Allianz	MCEV / SII based	SII/MCEV
Aviva	n/a	Adjusted SII
AXA	EEV / Adjusted SII	EEV
CNP	MCEV / SII based	MCEV
Delta Lloyd	n/a	SII
Generali	MCEV / SII based	SII / MCEV
Hannover Re	n/a	SII
JRP	IFRS based	EEV
L&G	n/a	Adjusted SII
Munich Re	n/a	SII
NN Group	n/a	Internal
Old Mutual EM	MCEV	MCEV
PIC	EEV + MCEV / SII based	EEV
Prudential	EEV	EEV
St James's Place	EEV	EEV



Further wish list

- Solvency 2 vs. IFRS earnings
- Embedded guarantees to policyholders
- Comparability of 1-in-200 scenarios, especially the macro risks
- More understanding of longevity risk
- Consistency...





The views expressed in this presentation are those of invited contributors and not necessarily those of the IFoA. The IFoA do not endorse any of the views stated, nor any claims or representations made in this presentation and accept no responsibility or liability to any person for loss or damage suffered as a consequence of their placing reliance upon any view, claim or representation made in this presentation.

The information and expressions of opinion contained in this presentation are not intended to be a comprehensive study, nor to provide actuarial advice or advice of any nature and should not be treated as a substitute for specific advice concerning individual situations. On no account may any part of this presentation be reproduced without the written permission of the IFoA or authors.

